newsfilter
← Latest News
PR Newswire·

Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events

JERUSALEM, Jan. 10, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that all ten patients in its US multi-center pilot trial of the Alpha DaRT for